The design and evaluation of the antimicrobial activity of a novel conjugated penta-ultrashort antimicrobial peptide in combination with conventional antibiotics against sensitive and resistant strains of S. aureus and E. coli.

Rula Darwish , Ammar Almaaytah , Ali Salama

Abstract


Background and purpose: Antimicrobial resistance still constitutes a major health concern to the global human population. The development of new classes of antimicrobial agents is urgently needed to thwart the continuous emergence of highly resistant microbial pathogens.

Experimental approach: In this study, we have rationally designed a novel conjugated ultrashort antimicrobial peptide. The peptide named naprolyginine was challenged against representative strains of wild-type and multidrug-resistant bacteria individually or in combination with individual antibiotics by employing standard antimicrobial and checkerboard assays.

Findings / Results: Our results displayed that the peptide exhibits potent synergistic antimicrobial activity against resistant strains of gram-positive and gram-negative bacteria when combined with individual antibiotics. Additionally, the peptide was evaluated for its hemolytic activity against human red blood cells and displayed negligible toxicity.

Conclusion and implications: Naprolyginine could prove to be a promising candidate for antimicrobial drug development.


Keywords


Antimicrobial peptides; Bacteria; Drug design; Hemolysis; Naproxen.

Full Text:

PDF

References


Gajdács M, Urbán E, Stájer A, Baráth Z. Antimicrobial resistance in the context of the sustainable development goals: a brief review. Eur J Investig Health Psychol Educ. 2021;11(1):71-82. DOI: 10.3390/ejihpe11010006.

Dadgostar P. Antimicrobial resistance: implications and costs. Infect Drug Resist. 2019;12:3903-3910. DOI: 10.2147/IDR.S234610.

Duval RE, Grare M, Demoré B. Fight against antimicrobial resistance: we always need new antibacterials but for right bacteria. Molecules. 2019;24(17):3152. DOI: 10.3390/molecules24173152.

Carlet J, Jarlier V, Harbarth S, Voss A, Goossens H, Pittet D. Ready for a world without antibiotics? The pensières antibiotic resistance call to action. Antimicrob Resist Infect Control. 2012;1(1):11,1-3. DOI: 10.1186/2047-2994-1-11

Wang J, Dou X, Song J, Lyu Y, Zhu X, Xu L, et al. Antimicrobial peptides: promising alternatives in the post feeding antibiotic era. Med Res Rev. 2019;39(3):831-859. DOI: 10.1002/med.21542.

Kosikowska P, Lesner A. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003-2015). Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015). Expert Opin Ther Pat. 2016;26(6):689-702. DOI: 10.1080/13543776.2016.1176149.

Chen CH, Lu TK. Development and challenges of antimicrobial peptides for therapeutic applications. Antibiotics (Basel). 2020;9(1):24, 1-20. DOI: 10.3390/antibiotics9010024.

Koo HB, Seo J. Antimicrobial peptides under clinical investigation. Pep Sci. 2019;111(5):e24122. DOI: 10.1002/pep2.24122.

Lazzaro BP, Zasloff M, Rolff J. Antimicrobial peptides: application informed by evolution. Science. 2020;368(6490):eaau5480. DOI: 10.1126/science.aau5480.

Sani MA, Separovic F. Antimicrobial peptide structures: from model membranes to live cells. Chemistry. 2018;24(2):286-291. DOI: 10.1002/chem.201704362.

Almaaytah A, Qaoud MT, Abualhaijaa A, Al-Balas Q, Alzoubi KH. Hybridization and antibiotic synergism as a tool for reducing the cytotoxicity of antimicrobial peptides. Infect Drug Resist. 2018;11:835-847. DOI: 10.2147/IDR.S166236.

Birteksoz-Tan AS, Zeybek Z, Hacioglu M, Savage PB, Bozkurt-Guzel C. In vitro activities of antimicrobial peptides and ceragenins against Legionella pneumophila. J Antibiot (Tokyo). 2019;72(5):291-297. DOI: 10.1038/s41429-019-0148-1.

Lee YC, Chen PY, Wang JT, Chang SC. A study on combination of daptomycin with selected antimicrobial agents: in vitro synergistic effect of MIC value of 1 mg/L against MRSA strains. BMC Pharmacol Toxicol. 2019;20(1):25,1-6. DOI: 10.1186/s40360-019-0305-y.

Patil SV, Hajare AL, Patankar M, Krishnaprasad K. In vitro fractional inhibitory concentration (FIC) study of cefixime and azithromycin fixed dose combination (FDC) against respiratory clinical isolates. J Clin Diagn Res. 2015;9(2):DC13-DC15. DOI: 10.7860/JCDR/2015/12092.5560.

Bidaud AL, Schwarz P, Herbreteau G, Dannaoui E. Techniques for the assessment of in vitro and in vivo antifungal combinations J Fungi (Basel). 2021;7(2):1-16. DOI: 10.3390/jof7020113.

Oh R, Lee MJ, Kim YO, Nam BH, Kong HJ, Kim JW, et al. Myticusin-beta, antimicrobial peptide from the marine bivalve, Mytilus coruscus. Fish Shellfish Immunol. 2020;99:342-352. DOI: 10.1016/j.fsi.2020.02.020.

Panteleev PV, Bolosov IA, Balandin SV, Ovchinnikova TV. Design of antimicrobial peptide arenicin analogs with improved therapeutic indices. J Pep Sci. 2015;21(2):105-113. DOI: 10.1002/psc.2732.

Shallcross LJ, Howard SJ, Fowler T, Davies SC. Tackling the threat of antimicrobial resistance: from policy to sustainable action. Philos Trans R Soc Lond B Biol Sci. 2015;370(1670):20140082. DOI: 10.1098/rstb.2014.0082.

McEwen SA, Collignon PJ. Antimicrobial resistance: a one health perspective. Microbiol Spectr. 2018;6(2):6-2. DOI: 10.1128/microbiolspec.ARBA-0009-2017.

Draenert R, Seybold U, Grützner E, Bogner JR. Novel antibiotics: are we still in the pre-post-antibiotic era? Infection. 2015;43(2):145-151. DOI: 10.1007/s15010-015-0749-y.

Mitra JB, Sharma VK, Kumar M, Mukherjee A. Antimicrobial peptides: vestiges of past or modern therapeutics? Mini Rev Med Chem. 2020; 20(3):183-195. DOI: 10.2174/1389557519666191125121407.

Almaaytah A, Qaoud MT, Khalil Mohammed G, Abualhaijaa A, Knappe D, Hoffmann R, et al. Antimicrobial and antibiofilm activity of UP-5, an ultrashort antimicrobial peptide designed using only arginine and biphenylalanine. Pharmaceuticals (Basel). 2018;11(1):1-18. DOI: 10.3390/ph11010003.

Bechinger B, Gorr SU. Antimicrobial peptides: mechanisms of action and resistance. J Dent Res. 2017;96(3):254-260. DOI: 10.1177/0022034516679973.

Salama, A. The development of a novel ultrashort antimicrobial peptide nanoparticles with potent antimicrobial effect. Pharmacia, 2022;69(1):255-260.‏DOI: 10.3897/pharmacia.69.e81954


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.